Gilead Sciences, Inc. (NASDAQ: GILD), a number one research-based biopharmaceutical firm, has reported a rise in revenues and adjusted earnings for the second quarter of 2024.
- Second-quarter income elevated 5% from final 12 months to $7.0 billion, aided by increased product gross sales in HIV, Liver Illness, and Oncology
- Earnings, on a per-share foundation, had been $1.29 within the second quarter, in comparison with $0.83 in the identical interval in 2023
- Adjusted earnings per share elevated to $2.01 within the June quarter from $1.34 within the prior-year interval
- Web revenue attributable to Gilead superior to $1.61 billion in Q2 from $1.05 billion within the year-ago quarter
- As of June 30, 2024, the corporate had $2.8 billion of money, money equivalents, and marketable debt securities, vs. $8.4 billion a 12 months earlier
- Throughout the quarter, Gilead generated $1.3 billion in working money movement; it paid dividends of $972 million and repurchased $100 million of frequent inventory
